Search Results - "Ahronian, L."

A novel KLF6-Rho GTPase axis regulates hepatocellular carcinoma cell migration and dissemination by Ahronian, L G, Zhu, L J, Chen, Y-W, Chu, H-C, Klimstra, D S, Lewis, B C

“…The presence of invasion into the extra-hepatic portion of the portal vein or the development of distant metastases renders hepatocellular carcinoma (HCC)…”
Get full text

664P Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors by Corcoran, R.B., Do, K.T., Cleary, J., Parikh, A., Yeku, O., Weekes, C.D., Ahronian, L., Mauri, G., Tian, J., Brugge, J., Juric, D., Flaherty, K.T., Sullivan, R.J., Clark, J., Heist, R., Matulonis, U.A., Liu, J.F., Shapiro, G.I.

Get full text

447PDPhase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours by Corcoran, R B, Do, K T, Cleary, J M, Parikh, A R, Yeku, O O, Weekes, C D, Veneris, J, Ahronian, L G, Mauri, G, Seventer, E E Van, Fetter, I J, Gurski, J M, Matulonis, U A, Juric, D, Flaherty, K T, Sullivan, R J, Clark, J W, Heist, R S, Shapiro, G I

“…Abstract Background MEK inhibitors (MEKi) lack single agent clinical efficacy in RAS mutant cancers, likely because MEKi produce only a cytostatic response in…”
Get full text